{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:02:14Z","timestamp":1789516934772,"version":"build-2803163510"},"reference-count":104,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>It is unclear whether blockade of the angiotensin system has effects on mental health. Our objective was to determine the impact of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor (AT1R) blockers on mental health domain of quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design:<\/jats:title>\n                    <jats:p>Meta-analysis of published literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>\n                      PubMed and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>\n                      databases. The last search was conducted in January 2017.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection:<\/jats:title>\n                    <jats:p>Randomized controlled trials comparing any angiotensin converting enzyme inhibitor or AT1R blocker versus placebo or non-angiotensin converting enzyme inhibitor or non-AT1R blocker were selected. Study participants were adults without any major physical symptoms. We adhered to meta-analysis reporting methods as per PRISMA and the Cochrane Collaboration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>\n                      Eleven studies were included in the analysis. When compared with placebo or other antihypertensive medications, AT1R blockers and angiotensin converting enzyme inhibitors were associated with improved overall quality of life (standard mean difference = 0.11, 95% confidence interval = [0.08, 0.14],\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.0001), positive wellbeing (standard mean difference = 0.11, 95% confidence interval = [0.05, 0.17],\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.0001), mental (standard mean difference = 0.15, 95% confidence interval = [0.06, 0.25],\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.0001), and anxiety (standard mean difference = 0.08, 95% confidence interval = [0.01, 0.16],\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.0001) domains of QoL. No significant difference was found for the depression domain (standard mean difference = 0.05, 95% confidence interval = [0.02, 0.12],\n                      <jats:italic>p<\/jats:italic>\n                      = 0.15).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Use of angiotensin blockers and inhibitors for the treatment of hypertension in otherwise healthy adults is associated with improved mental health domains of quality of life. Mental health quality of life was a secondary outcome in the included studies. Research specifically designed to analyse the usefulness of drugs that block the angiotensin system is necessary to properly evaluate this novel psychiatric target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0004867417721654","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T02:47:27Z","timestamp":1501296447000},"page":"24-38","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":46,"title":["Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials"],"prefix":"10.1177","volume":"52","author":[{"given":"Daniel J","family":"Brownstein","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Salagre","sequence":"additional","affiliation":[{"name":"Bipolar Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"K\u00f6hler","sequence":"additional","affiliation":[{"name":"Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Cear\u00e1, Fortaleza, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Faculty of Health, Social Care and Education, Anglia Ruskin University, Chelmsford, UK"},{"name":"Institute of Psychiatry, Psychology &amp; Neuroscience (IoPPN), King\u2019s College London, London, UK"},{"name":"Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Vian","sequence":"additional","affiliation":[{"name":"Psychiatry and Mental Health Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal"},{"name":"Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciria","family":"Pereira","sequence":"additional","affiliation":[{"name":"Psychiatry and Mental Health Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal"},{"name":"Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Chavarria","sequence":"additional","affiliation":[{"name":"Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar (PSM), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Karmakar","sequence":"additional","affiliation":[{"name":"Center for Pattern Recognition and Data Analytics, School of Information Technology, Deakin University, Geelong, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyna","family":"Turner","sequence":"additional","affiliation":[{"name":"IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia"},{"name":"Barwon Health, Geelong, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Quevedo","sequence":"additional","affiliation":[{"name":"Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA"},{"name":"Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA"},{"name":"Neuroscience Graduate Program, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center UTHealth, Houston, TX, USA"},{"name":"Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina (UNESC), Crici\u00fama, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 F","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Cear\u00e1, Fortaleza, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[{"name":"IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia"},{"name":"Barwon Health, Geelong, VIC, Australia"},{"name":"Orygen, the National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia"},{"name":"Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia"},{"name":"The Florey Institute for Neuroscience Mental Health, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brisa S","family":"Fernandes","sequence":"additional","affiliation":[{"name":"IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia"},{"name":"Barwon Health, Geelong, VIC, Australia"},{"name":"Laboratory of Calcium Binding Proteins in the Central Nervous System, Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.95"},{"key":"e_1_3_3_3_1","first-page":"36","article-title":"Effect of telmisartan on the psychological state and quality of life in stable hypertension patients","volume":"67","author":"Andreeva GF","year":"2004","unstructured":"Andreeva GF, Gorbunov VM, Aivazian TA, et al. (2004) Effect of telmisartan on the psychological state and quality of life in stable hypertension patients. Eksp Klin Farmakol 67: 36\u201340.","journal-title":"Eksp Klin Farmakol"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.03.013"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400090099018"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.225"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2010.10.001"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08188"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/00004872-199509000-00018","article-title":"A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: Field trial in general practice. The OCAPI Study Group. Optimiser le Choix d\u2019un Anti-hypertenseur de Premiere Intention","volume":"13","author":"Boissel JP","year":"1995","unstructured":"Boissel JP, Collet JP, Lion L, et al. (1995) A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: Field trial in general practice. The OCAPI Study Group. Optimiser le Choix d\u2019un Anti-hypertenseur de Premiere Intention. Journal of Hypertension 13: 1059\u20131067.","journal-title":"Journal of Hypertension"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22595"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0560-3"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-41"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01857642"},{"key":"e_1_3_3_14_1","first-page":"750","article-title":"Quality of life perception during antihypertensive treatment: A comparative study of bisoprolol and enalapril","volume":"20","author":"Breed JG","year":"1992","unstructured":"Breed JG, Ciampricotti R, Tromp GP, et al. (1992) Quality of life perception during antihypertensive treatment: A comparative study of bisoprolol and enalapril. Journal of Cardiovascular Pharmacology 20: 750\u2013755.","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001282"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199301000-00012"},{"key":"e_1_3_3_17_1","first-page":"545","article-title":"Blood pressure control and quality of life: A comparative multicenter double-blind and cross-over trial of labetalol and captopril","volume":"9","author":"Carre A","year":"1988","unstructured":"Carre A, Petetin N, Jouvent R, et al. (1988) Blood pressure control and quality of life: A comparative multicenter double-blind and cross-over trial of labetalol and captopril. La Revue de M\u00e9decine Interne 9: 545\u2013553.","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357500"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000441457"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291716000957"},{"key":"e_1_3_3_21_1","first-page":"749","article-title":"Differential clinical profile of candesartan compared to other angiotensin receptor blockers","volume":"7","author":"Cernes R","year":"2011","unstructured":"Cernes R, Mashavi M, Zimlichman R (2011) Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vascular Health and Risk Management 7: 749\u2013759.","journal-title":"Vascular Health and Risk Management"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(96)00060-X"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020648405680"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.8.1012"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000687"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/7.4.329"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00040031733024"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198606263142602"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2005.04.017"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715110-00018"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02220612"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.08.005"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001657"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050625"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1991.tb00434.x"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15r09984"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0849-x"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.19.6.499"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199005000-00011"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80034-5"},{"key":"e_1_3_3_42_1","first-page":"215","article-title":"Quality of life, side effects and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension","volume":"5","author":"Frimodt-Moeller J","year":"1991","unstructured":"Frimodt-Moeller J, Poulsen DL, Kornerup HJ, et al. (1991) Quality of life, side effects and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension. Journal of Human Hypertension 5: 215\u2013221.","journal-title":"Journal of Human Hypertension"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.06.006"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(88)90010-8"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22195"},{"key":"e_1_3_3_46_1","unstructured":"Glik DC Steadman MS Michels PJ et al. (1990) Antihypertensive regimen and quality of life in a disadvantaged population. Journal of Family Practice 30: 143\u2013149; discussion 150\u2013152."},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60692-4"},{"key":"e_1_3_3_48_1","first-page":"28","article-title":"Changes in the quality of life influenced by treatment of primary arterial hypertension","volume":"2","author":"Gralec M","year":"1997","unstructured":"Gralec M, Piusinska-Macoch A, Cholewa M, et al. (1997) Changes in the quality of life influenced by treatment of primary arterial hypertension. Polski Merkuriusz Lekarski 2: 28\u201331.","journal-title":"Polski Merkuriusz Lekarski"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2014.07.018"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)90582-3"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90340-9"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000186736.99523.1d"},{"key":"e_1_3_3_53_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins JPT","year":"2011","unstructured":"Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. London: The Cochrane Collaboration."},{"key":"e_1_3_3_54_1","first-page":"S91","article-title":"Angiotensin converting enzyme inhibitors and quality of life: The European trial","volume":"3","author":"Hill JF","year":"1985","unstructured":"Hill JF, Bulpitt CJ, Fletcher AE (1985) Angiotensin converting enzyme inhibitors and quality of life: The European trial. Journal of Hypertension 3: S91\u2013S94.","journal-title":"Journal of Hypertension"},{"key":"e_1_3_3_55_1","first-page":"302","article-title":"Quality of life of patients with mild hypertension treated with captopril: A randomized double-blind placebo-controlled clinical trial","volume":"112","author":"Hu Y","year":"1999","unstructured":"Hu Y, Zhu J (1999) Quality of life of patients with mild hypertension treated with captopril: A randomized double-blind placebo-controlled clinical trial. Chinese Medical Journal 112: 302\u2013307.","journal-title":"Chinese Medical Journal"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-011-9641-y"},{"key":"e_1_3_3_57_1","volume-title":"Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Jp H","year":"2011","unstructured":"Jp H (2011) Handbook for Systematic Reviews of Interventions Version 5.1.0. London: The Cochrane Collaboration."},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700046377"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2011.11.005"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0594.2011.00746.x"},{"key":"e_1_3_3_61_1","first-page":"393","article-title":"Ramipril and methyldopa compared in patients with mild to moderate hypertension","volume":"12","author":"Kundu SC","year":"1990","unstructured":"Kundu SC, Bhattacharya A, Vakil HB (1990) Ramipril and methyldopa compared in patients with mild to moderate hypertension. Clinical Therapeutics 12: 393\u2013397.","journal-title":"Clinical Therapeutics"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(97)82681-5"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(88)91089-3"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-9-199711010-00008"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(95)00053-R"},{"key":"e_1_3_3_66_1","first-page":"357","article-title":"Effects of antihypertensive medications on vitality and well-being","volume":"25","author":"Levine S","year":"1987","unstructured":"Levine S, Croog SH, Sudilovsky A, et al. (1987) Effects of antihypertensive medications on vitality and well-being. Journal of Family Practice 25: 357\u2013363.","journal-title":"Journal of Family Practice"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440040047006"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5465"},{"key":"e_1_3_3_69_1","first-page":"504","volume-title":"American Journal of Hypertension","author":"Malmqvist K","year":"2000","unstructured":"Malmqvist K, Kahan T, Dahl M (2000) Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: Benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. American Journal of Hypertension 13: 504\u2013511."},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-015-0216-6"},{"key":"e_1_3_3_71_1","first-page":"300","article-title":"Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients","volume":"12","author":"Mccorvey EJR","year":"1993","unstructured":"Mccorvey EJR, Wright JTJR, Culbert JP, et al. (1993) Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clinical Pharmacy 12: 300\u2013305.","journal-title":"Clinical Pharmacy"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199401000-00004"},{"key":"e_1_3_3_73_1","first-page":"88","article-title":"A double-blind comparison of transdermal clonidine and oral captopril in essential hypertension","volume":"12","author":"McMahon FG","year":"1990","unstructured":"McMahon FG, Jain AK, Vargas R, et al. (1990) A double-blind comparison of transdermal clonidine and oral captopril in essential hypertension. Clinical Therapeutics 12: 88\u2013100.","journal-title":"Clinical Therapeutics"},{"key":"e_1_3_3_74_1","first-page":"29","article-title":"The Multicenter Captopril and the Quality of Life Study: The effect of antihypertensive agents from the basic groups on the quality of life of patients in different populations. The working group of the Multicenter Captopril and the Quality of Life Study","volume":"68","author":"Metelitsa VI","year":"1996","unstructured":"Metelitsa VI, Duda SG, Ostrovskaia TP, et al. (1996) The Multicenter Captopril and the Quality of Life Study: The effect of antihypertensive agents from the basic groups on the quality of life of patients in different populations. The working group of the Multicenter Captopril and the Quality of Life Study. Terapevticheskii Arkhiv 68: 29\u201336.","journal-title":"Terapevticheskii Arkhiv"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2013.09.006"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510060059034"},{"key":"e_1_3_3_77_1","first-page":"103","volume-title":"Journal of Hypertension","author":"Omvik P","year":"1993","unstructured":"Omvik P, Thaulow E, Herland OB, et al. (1993) Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: A multicentre study. Journal of Hypertension 11: 103\u2013113."},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80212-8"},{"key":"e_1_3_3_79_1","first-page":"S382","article-title":"Lisinopril and nifedipine in essential hypertension: A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients","volume":"9","author":"Os I","year":"1991","unstructured":"Os I, Bratland B, Dahlof B, et al. (1991) Lisinopril and nifedipine in essential hypertension: A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. Journal of Hypertension 9: S382\u2013S383.","journal-title":"Journal of Hypertension"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.3109\/08037059609062105"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199211000-00014"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(96)00253-1"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90118-X"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2014.05.006"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001283"},{"key":"e_1_3_3_86_1","doi-asserted-by":"crossref","unstructured":"Rasmussen S Borrild N Vang Andersen J (2006) Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg\/day or 2.5 mg\/day and potassium chloride compared with enalapril 10 mg\/day and amlodipine 5 mg\/day in patients with mild to moderate primary hypertension: A multicentre randomised open study. Clinical Drug Investigation 26: 91\u2013101.","DOI":"10.2165\/00044011-200626020-00004"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199805000-00015"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.04.047"},{"key":"e_1_3_3_89_1","first-page":"348","article-title":"Quality of life of hypertensive physicians with hypertension therapy. Randomized double-blind study of 237 female and male physicians with high blood pressure","volume":"109","author":"Siegrist J","year":"1991","unstructured":"Siegrist J, Middeke M, Osterkorn K (1991) Quality of life of hypertensive physicians with hypertension therapy. Randomized double-blind study of 237 female and male physicians with high blood pressure. Fortschritte Der Medizin 109: 348\u2013352.","journal-title":"Fortschritte Der Medizin"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006199-200301000-00009"},{"key":"e_1_3_3_91_1","first-page":"217","article-title":"Antihypertensive therapy and quality of life: A comparison of atenolol, captopril, enalapril and propranolol","volume":"4","author":"Steiner SS","year":"1990","unstructured":"Steiner SS, Friedhoff AJ, Wilson BL, et al. (1990) Antihypertensive therapy and quality of life: A comparison of atenolol, captopril, enalapril and propranolol. Journal of Human Hypertension 4: 217\u2013225.","journal-title":"Journal of Human Hypertension"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00165-X"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00156-9"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304013281302"},{"key":"e_1_3_3_95_1","first-page":"33","article-title":"\u2018The Goteborg quality of life instrument\u2019: An assessment of well-being and symptoms among men born 1913 and 1923. Methods and validity","volume":"1","author":"Tibblin G","year":"1990","unstructured":"Tibblin G, Tibblin B, Peciva S, et al. (1990) \u2018The Goteborg quality of life instrument\u2019: An assessment of well-being and symptoms among men born 1913 and 1923. Methods and validity. Scandinavian Journal of Primary Health Care 1: 33\u201338.","journal-title":"Scandinavian Journal of Primary Health Care"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2005.03.733"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80022-1"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000180457.82483.6b"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(96)00116-1"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(05)80024-8"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1159\/000444646"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2008.07837.x"},{"key":"e_1_3_3_104_1","first-page":"S155","article-title":"Captopril as a replacement for multiple therapy in hypertension: A controlled study","volume":"3","author":"Yodfat Y","year":"1985","unstructured":"Yodfat Y, Fidel J, Bloom DS (1985) Captopril as a replacement for multiple therapy in hypertension: A controlled study. Journal of Hypertension 3: S155\u2013S158.","journal-title":"Journal of Hypertension"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.08.027"}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0004867417721654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0004867417721654","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0004867417721654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:55:37Z","timestamp":1777373737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0004867417721654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1177\/0004867417721654"],"URL":"https:\/\/doi.org\/10.1177\/0004867417721654","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]}}}